Mitigating and learning from the impact of COVID‐19 infection on addictive disorders by Marsden, J. et al.
This is a repository copy of Mitigating and learning from the impact of COVID 19 infection ‐
on addictive disorders.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/160151/
Version: Published Version
Article:
Marsden, J., Darke, S., Hall, W. et al. (6 more authors) (2020) Mitigating and learning from 
the impact of COVID 19 infection on addictive disorders. Addiction. ISSN 0965-2140 ‐
https://doi.org/10.1111/add.15080
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Mitigating and learning from the impact of COVID-19
infection on addictive disorders
The COVID-19 pandemic and the measures required to
address it are cutting a swathe through people’s lives and the
global economy. People with addictive disorders are
particularly badly affected as a result of poverty, physical
and mental health vulnerabilities and disruption of access to
services. The pandemic may well increase the extent and
severity of some addictive disorders. Current research is
suffering from the termination of face-to-face data collection
and other restrictions. There is an urgent need to coordinate
efforts nationally and internationally to mitigate these
problems and to find innovative ways of continuing to
provide clinical and public health services to help people with
addictive disorders.
The novel coronavirus (COVID-19) pandemic of 2020
presents vast challenges to humanity, and particularly to
vulnerable populations world-wide. This includes particular
threats to people with addictive disorders, and public health
and clinical services to address their needs. This editorial
summarizes many of the issues and calls for a coordinated
effort to address them.
OPIOIDS
In recent years, many countries have experienced sharp in-
creases in opioid use disorder (OUD) and fatal opioid poi-
sonings [1,2]. COVID-19 is likely to compound this.
People with OUD have a high prevalence of coexisting
health problems, including chronic obstructive pulmonary
disease [3]. Many live in geographical areas characterized
by social deprivation, high population densities,
poor-quality housing and homelessness [4,5]. Together,
these conditions make it more likely that people with
OUD will have elevated rates of COVID-19 infection and
transmission.
Social distancing and treatment, staff sickness and
absences are straining the ability of OUD clinics to operate
effectively, although many have stayed open, at least in
some countries. It is essential that patients can continue
to access medication for OUD. In the United Kingdom,
new government advice asks services to transfer as many
patients as possible from supervised consumption to take-
home doses, with a 14-day supply for self-administration.
More flexibility is recommended for patients opting for
buprenorphine over methadone. Patients self-isolating are
advised to nominate someone to collect the dispensed
medicine on their behalf [6]. While this social distancing
response targets reduced COVID-19 exposure, it may
inadvertently increase medication diversion and fatal
opioid poisoning. In the community, disruption to the
supply of illicit opioids and increases in price could have
several effects, including a surge in treatment seekers,
more cases of overdose from the consumption of other opi-
oids and increased harms associated with the substitution
of opioids with other more readily available substances,
such as alcohol, cocaine and benzodiazepines.
STIMULANTS
People who smoke crack cocaine may be likely to experi-
ence more severe COVID-19 disease because they already
have greater inflammation of, and damage to, lung tissue
[7]. Stimulant use more generally puts people at greater
risk of cardiovascular disease, and this is a major risk factor
for mortality with COVID-19 infection [8].
ALCOHOL
Much of the debate concerning alcohol during the early
phases of the pandemic has focused on the restrictions
placed on sales, either through the enforced closure of
on-trade venues—such as pubs, bars and restaurants—or
the decisions taken by public bodies on whether off-trade
sales can continue through shops and supermarkets [9].
In places where all alcohol sales outlets are closed drinking
can be expected to decrease significantly [10], although
this effect may be moderated if stockpiling behaviour oc-
curred immediately before the imposition of restrictions.
The closure of all alcohol outlets may improve health and
reduce intimate partner violence, as well as other violence.
However, social isolation may heighten domestic tensions
negating or reversing this possible benefit. In jurisdictions
where off-trade outlets remain open, the overall changes
in levels and patterns of alcohol consumption are difficult
to predict, but there is evidence already of a significant
increase in alcohol sales [11]. The closure of on-trade
premises will probably affect how people drink (e.g. the
emergence of new social practices involving alcohol
consumption, such as online pub quizzes, dinner dates
and parties) rather than a simple substitution of consump-
tion from the on-trade to the off-trade [12].
For people with alcohol use disorder, there are addi-
tional concerns that some heavy drinkers will be at risk of
serious symptoms of withdrawal if they stop or reduce alco-
hol consumption and it may be hard to access medical
care. Some organizations are offering personalized
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guidance on this topic to try and ensure that reductions in
alcohol consumption are achieved safely at a time when
the usual sources of support and advice relating to detoxi-
fication may be less available [13].
TOBACCO USE
Smoking and associated respiratory disease may exacer-
bate COVID-19 severity [14]. Although sales of tobacco
products may not decline in the short term if consumers
can continue to purchase from shops and other outlets,
there are particular risks from the disruption of
e-cigarette supply chains. High street e-cigarette outlets
have been closed down in many jurisdictions, although
supplies still appear to be available on-line. With curtailed
supply of refills and e-cigarette components and slower
delivery schedules for non-essential commodities, some
e-cigarette users may relapse to smoking tobacco.
GAMBLING
Where casinos and other gambling venues have closed
there are anecdotal reports of increased on-line gambling
and gaming [15], although the cessation of most profes-
sional sport globally may also exert a downward pressure
on gambling. Financial pressures and concerns, social iso-
lation and stress—likely to be felt particularly among peo-
ple with job insecurity or recent unemployment—may
motivate gambling initiation or exacerbate problem
gambling. Industry reactions to new players or repeat
players who are gambling more intensively merit careful
monitoring.
RESEARCH
Participant enrolment and primary data collection have
stopped in many clinical and psychosocial studies. It is, of
course, hoped that these studies will resume, but
researchers are likely to need additional funding and will
have to incorporate sensitivity checks and other additions
to their statistical analysis plans. More positively, there
are examples of institutional review boards efficiently
fast-tracking newand amended research protocols to study
the impact of COVID-19 on populations with addictive
disorders.
Creative methodological innovations, including
internet-enabled primary data collection [16], are already
emerging to circumvent the current restrictions on field-
work. This will present both opportunities and challenges
with regard to selecting appropriate platforms (e.g. video,
voice- or text-based communication), sampling and
representativeness, establishing rapport with participants,
participant retention and safe data storage, with particular
challenges for studies involving populations with limited
digital access. Emerging techniques, such as wastewater
studies, can also provide valuable additions to more tradi-
tional research approaches [17].
Natural experimental designs, including multiple time–
series analysis, process evaluations, qualitative research
and longitudinal surveys, will be needed to understand
and estimate the effects of COVID-19 on addictive disor-
ders, treatment engagement and effectiveness and broader
treatment outcomes. Mixed-methods studies will also be
required to explore adaptive changes to individual recovery
and tomutual aid networks, and to ascertain howany shift
towards on-line and digital treatments and telemedicine,
are embraced, or not, particularly by those with limited
digital confidence and resources.
Research priorities will need to change as the pandemic
unfolds and new issues materialize. For example, if and
when countries are able to mountmass testing campaigns,
there will be questions concerning equity in access for
people with addictive disorders. Similarly, if and when an
effective vaccine is developed, it will be crucial to monitor
and address access and take-up by people with addictive
disorders. Given the numbers of people involved, when
one considers tobacco users and people with alcohol use
disorder, it will be important to adapt predictive modelling
for the population as a whole.
GENERAL ISSUES
Poverty, poor mental health and insecurity will be greatly
exacerbated by COVID-19 and social distancing measures,
and this will affect people with addictive disorders particu-
larly hard. An additional concern is evidence that addictive
behaviours are exacerbated when there are few other pos-
itive reinforcers in the environment—such as pleasurable
things to do and people with whom to interact [18]. We
may therefore experience a worsening of problems in
people who currently have problems, relapse in people
who have recovered and onset in people who are vulnera-
ble. It will be crucial to monitor this and take action to
mitigate the problem through protective policies and
societal initiatives.
CONCLUSIONS
COVID-19 infection and the measures used to address it
will probably exacerbate the multiple risk factors for the
initiation of addictive behaviours and the maintenance,
worsening and relapse of addictive disorders. We are all
prone to experience anxiety due to the disruptions
COVID-19 has had on our daily lives; uncertainty about
the future, loneliness, depression or even suicidality
induced by social distancing; and stress and grief from
the illness or death of loved ones. These emotions are likely
to place us at increased risk of a range of unhealthy
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behaviours and coping strategies, including substance use
and gambling.
Some drug and alcohol services will innovate—provid-
ing novel ways of delivering harm reduction, flexible access
to essential medications and internet and
telephone-delivered individual and group-based psychoso-
cial interventions. In many countries and regions, how-
ever, access to treatment services and treatment will be
limitedmore than ever, particularly for those who are most
vulnerable. Thiswill also probably be reflected in relation to
access to medical treatment for COVID-19 infection.
There will be differences among countries in the
experience of problems associated with COVID-19, and it
is crucial that we learn from each other. We must take
the opportunity to share information about the problems,
the solutions being tried and the outcomes of these efforts.
This requires coordination by supranational agencies, with
scientific, clinical and public health organizations all
playing a role.
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